Page 180 - Vitamin D and Cancer

7 Induction of Differentiation in Cancer Cells by Vitamin D 167

62. McGaffin KR, Acktinson LE, Chrysogelos SA (2004) Growth and EGFR regulation in breast
cancer cells by vitamin D and retinoid compounds. Breast Cancer Res Treat 86:55–73
63. McGaffin KR, Chrysogelos SA (2005) Identification and characterization of a response
element in the EGFR promoter that mediates transcriptional repression by 1, 25-dihydroxyvi-

tamin D3 in breast cancer cells. J Mol Endocrinol 35:117–133
64. Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP (2000) The anti-proliferative
effects of 1alpha, 25(OH) D3 on breast and prostate cancer cells are associated with induc-
2
tion of BRCA1 gene expression. Oncogene 19:5091–5097
65. Lazzaro G, Agadir A, Qing W, Poria M, Mehta RR, Moriarty RM, Das Gupta TK, Zhang
XK, Mehta RG (2000) Induction of differentiation by 1alpha-hydroxyvitamin D in T47D
5
human breast cancer cells and its interaction with vitamin D receptors. Eur J Cancer
36:780–786
66. Peng X, Jhaveri P, Hussain-Hakimjee EA, Mehta RG (2007) Overexpression of ER and VDR
is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-
hydroxyvitamin D . Carcinogenesis 28:1000–2007
5
67. Campbell MJ, Reddy GS, Koeffler HP (1997) Vitamin D3 analogs and their 24-oxo metabo-
lites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecu-
lar effects. J Cell Biochem 66:413–425
68. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin
Z, Day RS, Trump DL, Johnson CS (1997) Vitamin D inhibition of prostate adenocarcinoma
growth and metastasis in the Dunning rat prostate model system. Urology 50:999–1006
69. Zhao XY, Feldman D (2001) The role of vitamin D in prostate cancer. Steroids 66:293–300
70. Krishnan AV, Peehl DM, Feldman D (2003) Inhibition of prostate cancer growth by vitamin
D: Regulation of target gene expression. J Cell Biochem 88:363–71
71. Beer TM, Garzotto M, Park B, Mori M, Myrthue A, Janeba N, Sauer D, Eilers K (2006)
Effect of calcitriol on prostate-specific antigen in vitro and in humans. Clin Cancer Res
12:2812–2816
72. Reiter W (1999) The clinical value of the Enzymun-Test for total and free PSA – a multi-
centre evaluation. Anticancer Res 19:5559–5562
73. Konety BR, Schwartz GG, Acierno JS Jr, Becich MJ, Getzenberg RH (1996) The role of
vitamin D in normal prostate growth and differentiation. Cell Growth Differ 7:1563–1570
74. Floryk D, Tollaksen SL, Giometti CS, Huberman E (2004) Differentiation of human prostate
cancer PC-3 cells induced by inhibitors of inosine 5¢-monophosphate dehydrogenase. Cancer
Res 64:9049–9056
75. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP (1997) Inhibition of prolif-
eration of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the
induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19:15–27
76. Ortel B, Sharlin D, ÓDonnell D, Sinha AK, Maytin EV, Hasan T (2002) Differentiation
enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer
cells. Br J Cancer 87:1321–1327
77. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D (2004)
Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells
using cDNA microarrays. Prostate 59:243–251
78. Boyle BJ, Zhao XY, Cohen P, Feldman D (2001) Insulin-like growth factor binding protein-3
mediates 1 alpha, 25-dihydroxyvitamin D3 growth inhibition in the LNCaP prostate cancer
cell line through p21/WAF1. J Urol 165:1319–1324
79. Paralkar VM, Vail AL, Grasser WA, Brown TA, Xu H, Vukicevic S, Ke HZ, Qi H, Owen TA,
Thompson DD (1998) Cloning and characterization of a novel member of the transforming
growth factor-beta/bone morphogenetic protein family. J Biol Chem 273:13760–13767
80. Zhao XY, Ly LH, Peehl DM, Feldman D (1999) Induction of androgen receptor by 1alpha,
25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Endocrinology 140:1205–1212
81. Zhao XY, Peehl DM, Navone NM, Feldman D (2000) 1alpha, 25-dihydroxyvitamin D3 inhibits
prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Endocrinology 141:2548–2556